Levodopa/Carbidopa/Entacapone Stada Arzneimittel Ag (Carbidopa, Entacapone, Levodopa)

Levodopa/Carbidopa/Entacapone is used within the antiparkinson therapeutic class to manage motor symptoms of Parkinson's disease.

• Parkinson's disease: improves overall motor function and reduces rigidity and bradykinesia.
• Wearing‑off phenomenon: decreases the duration of OFF periods between levodopa doses.
• Motor fluctuations: stabilises dopaminergic response and lessens dyskinesia severity.

• Levodopa is a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine in the central nervous system. Carbidopa inhibits peripheral dopa decarboxylase, preventing premature conversion of levodopa and increasing its cerebral availability. Entacapone blocks catechol‑O‑methyltransferase (COMT), reducing peripheral levodopa metabolism and prolonging its therapeutic effect, together providing more consistent dopaminergic stimulation.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: often related to orthostatic changes.
• Headache: transient and usually resolves.
• Insomnia: difficulty initiating or maintaining sleep.
• Orthostatic hypotension: drop in blood pressure upon standing.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Hallucinations: visual or auditory disturbances.
• Severe hypotension: may lead to fainting.
• Dyskinesia: involuntary movements that can be disabling.
• Neuroleptic malignant syndrome: rare but life‑threatening reaction.
• Anaphylactic reaction: acute allergic response requiring immediate care.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Renal impairment: adjust therapy as renal clearance may be reduced.
• Hepatic impairment: use with caution; liver function may affect metabolism.
• Cardiovascular disease: monitor blood pressure and heart rate closely.
• Psychiatric disorders: assess for hallucinations or confusion, especially in older adults.
• Concomitant dopamine antagonists: avoid or adjust dose to prevent reduced efficacy.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: risk of hypertensive crisis.
• Antipsychotics (dopamine antagonists): may diminish antiparkinson effect.
• High‑dose pyridoxine (vitamin B6): can increase peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive blood‑pressure lowering effect.
• Iron or antacids: may reduce levodopa absorption; separate dosing by at least 2 hours.
• SSRIs or SNRIs: monitor for serotonin syndrome when combined with MAO‑B inhibitors.
• Diuretics: watch for electrolyte disturbances that could affect blood pressure.